Pretreatment whole blood Epstein-Barr virus DNA predicts prognosis in Hodgkin lymphoma

被引：6
作者：
Qin, Jia-Qi [1 ,2 ,3 ]
Yin, Hua [1 ,2 ,3 ]
Wu, Jia-Zhu [1 ,2 ,3 ]
Chen, Rui-Ze [1 ,2 ,3 ]
Xia, Yi [1 ,2 ,3 ]
Wang, Li [1 ,2 ,3 ]
Zhu, Hua-Yuan [1 ,2 ,3 ]
Fan, Lei [1 ,2 ,3 ]
Li, Jian-Yong [1 ,2 ,3 ]
Liang, Jin-Hua [1 ,2 ,3 ]
Xu, Wei [1 ,2 ,3 ]
机构：
[1] Nanjing Med Univ, Jiangsu Prov Hosp, Affiliated Hosp 1, Dept Hematol, Nanjing 210029, Peoples R China
[2] Nanjing Med Univ, Key Lab Hematol, Nanjing 210029, Peoples R China
[3] Collaborat Innovat Ctr Canc Personalized Med, Nanjing 210029, Peoples R China
来源：
LEUKEMIA RESEARCH | 2021年 / 107卷
基金：
中国国家自然科学基金;
关键词：
EBV DNA; Hodgkin lymphoma; Overall survival; Prognosis; Progression-Free survival; POSITRON-EMISSION-TOMOGRAPHY; EBV-DNA; LYMPHOPROLIFERATIVE DISORDERS; CLINICAL-SIGNIFICANCE; MONONUCLEAR-CELLS; PLASMA; EXPRESSION; LOAD;
D O I：
10.1016/j.leukres.2021.106607
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The study investigated pretreatment Epstein-Barr virus (EBV) DNA status and its prognostic values in 96 patients newly diagnosed Hodgkin lymphoma (HL). With 13.5 % patients in positive EBV DNA status before therapy, the positive group had inferior progression-free survival (PFS) (P = 0.023) as well as overall survival (OS) (P = 0.001). Pretreatment EBV DNA positivity was observed as an independent prognostic factor in OS (P = 0.036) while a trend to predict PFS (P = 0.064). By monitoring changes of EBV DNA copies in 13 patients with positive pretreatment EBV DNA status, 5 of 6 patients with complete response (CR) had their copies undetectable after 3 cycles of first-line treatment and 7 patients with progressive disease (PD) all had elevated EBV DNA copies during their relapsed period. Whole blood EBV DNA may be an adjunctive biomarker to reflect treatment response, risk of disease relapse as well as prognosis in HL patients.
引用
收藏
页数：6
相关论文
共 34 条
[1]   Recent Advances in Diagnostic Approaches for Epstein-Barr Virus [J].
Abusalah, Mai Abdel Haleem ;
Gan, Siew Hua ;
Al-Hatamleh, Mohammad A. I. ;
Irekeola, Ahmad Adebayo ;
Shueb, Rafidah Hanim ;
Yean, Chan Yean .
PATHOGENS, 2020, 9 (03)
[2]   Age-related Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders: comparison with EBV-positive classic Hodgkin lymphoma in elderly patients [J].
Asano, Naoko ;
Yamamoto, Kazuhito ;
Tamaru, Jun-Ichi ;
Oyama, Takashi ;
Ishida, Fumihiro ;
Ohshima, Koichi ;
Yoshino, Tadashi ;
Nakamura, Naoya ;
Mori, Shigeo ;
Yoshie, Osamu ;
Shimoyama, Yoshie ;
Morishima, Yasuo ;
Kinoshita, Tomohiro ;
Nakamura, Shigeo .
BLOOD, 2009, 113 (12) :2629-2636
[3]   Special Report: Policy A review of human carcinogens-Part F: Chemical agents and related occupations [J].
Baan, Robert ;
Grosse, Yann ;
Straif, Kurt ;
Secretan, Beatrice ;
El Ghissassi, Fatiha ;
Bouvard, Veronique ;
Benbrahim-Tallaa, Lamia ;
Guha, Neela ;
Freeman, Crystal ;
Galichet, Laurent ;
Cogliano, Vincent .
LANCET ONCOLOGY, 2009, 10 (12) :1143-1144
[4]  
Chan KCA, 2003, CANCER RES, V63, P2028
[5]   The clinical significance of Epstein-Barr virus DNA in peripheral blood mononuclear cells in patients with non-Hodgkin lymphoma [J].
Chen, Yi ;
Zheng, Xiaoyun ;
Chen, Buyuan ;
Yang, Xiaozhu ;
Zheng, Jing ;
Zheng, Zhihong ;
Yang, Ting ;
Liu, Tingbo ;
Hu, Jianda .
LEUKEMIA & LYMPHOMA, 2017, 58 (10) :2349-2355
[6]   Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification [J].
Cheson, Bruce D. ;
Fisher, Richard I. ;
Barrington, Sally F. ;
Cavalli, Franco ;
Schwartz, Lawrence H. ;
Zucca, Emanuele ;
Lister, T. Andrew .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3059-+
[7]   Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Eichenauer, D. A. ;
Aleman, B. M. P. ;
Andre, M. ;
Federico, M. ;
Hutchings, M. ;
Illidge, T. ;
Engert, A. ;
Ladetto, M. .
ANNALS OF ONCOLOGY, 2018, 29 :19-29
[8]   Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma [J].
Gandhi, MK ;
Lambley, E ;
Burrows, J ;
Dua, U ;
Elliott, S ;
Shaw, PJ ;
Prince, HM ;
Wolf, M ;
Clarke, K ;
Underhill, C ;
Mills, T ;
Mollee, P ;
Gill, D ;
Marlton, P ;
Seymour, JF ;
Khanna, R .
CLINICAL CANCER RESEARCH, 2006, 12 (02) :460-464
[9]   DNA methylation enzymes and PRC1 restrict B-cell Epstein-Barr virus oncoprotein expression [J].
Guo, Rui ;
Zhang, Yuchen ;
Teng, Mingxiang ;
Jiang, Chang ;
Schineller, Molly ;
Zhao, Bo ;
Doench, John G. ;
O'Reilly, Richard J. ;
Cesarman, Ethel ;
Giulino-Roth, Lisa ;
Gewurz, Benjamin E. .
NATURE MICROBIOLOGY, 2020, 5 (08) :1051-+
[10]   The Viral Load of Epstein-Barr Virus (EBV) DNA in Peripheral Blood Predicts for Biological and Clinical Characteristics in Hodgkin Lymphoma [J].
Hohaus, Stefan ;
Santangelo, Rosaria ;
Giachelia, Manuela ;
Vannata, Barbara ;
Massini, Giuseppina ;
Cuccaro, Annarosa ;
Martini, Maurizio ;
Cesarini, Valeriana ;
Cenci, Tonia ;
D'Alo, Francesco ;
Voso, Maria Teresa ;
Fadda, Giovanni ;
Leone, Giuseppe ;
Larocca, Luigi M. .
CLINICAL CANCER RESEARCH, 2011, 17 (09) :2885-2892
1234